Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement

AlBloushi, Abdulrahman F; Herbort, Carl P.; El‐Asrar, Ahmed M. Abu

doi:10.1007/s10792-021-01989-6

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VKH occurs bilaterally; however, the effects may be asymmetric [46]. For instance, a unilateral retinal detachment that occurs at onset can evolve into bilateral retinal detachment, when not appropriately treated [47]. Prompt detection of the disease with adequate choroidal evaluation is fundamental.…”

Section: Description Of Initial-onset and Chronic Vkh Diseasementioning

confidence: 99%

Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review

Urzua

Herbort²,

Takeuchi

et al. 2022

J Ophthal Inflamm Infect

Self Cite

View full text Add to dashboard Cite

Background Appraisals of Vogt-Koyanagi-Harada disease (VKH) have become progressively more complete, since its first description in 1906. The availability of new investigational methods has improved our knowledge of the immunopathology, clinicopathology, diagnosis, and management of VKH disease. This review aimed to describe some of the steps that led to better characterization of VKH as a clinical entity. Methods We searched on PubMed for articles that described the history of VKH disease and analyzed the progress in disease appraisal with new investigational and imaging methods. In particular, we searched for articles that investigated the clinicopathology, diagnosis, and management of VKH. Findings The following developments were considered essential for improving the appraisal and understanding of VKH: (1) the history of the disease, (2) immunopathological mechanisms, (3) clinicopathology, (4) the importance of distinguishing initial-onset from chronic disease, (5) relevant imaging modalities, among which indocyanine green angiography is crucial, (6) diagnostic criteria that facilitate early diagnosis, and (7) the need for early, prolonged, aggressive treatment that combines steroidal and non-steroidal immunosuppression. Conclusion Based on these findings, the definition of VKH has improved. VKH disease starts in the choroidal stroma and later involves other structures when it is not diagnosed and treated early. Indocyanine green angiography and enhanced depth imaging optical coherence tomography facilitate early diagnosis and precise monitoring of choroidal inflammation. ICGA is clearly the gold standard for appraisals and follow-ups in VKH disease, however EDI-OCT should be especially considered in those areas where ICGA is not fully available. These modalities have contributed substantially to a “cure” for VKH, when treatment is introduced within the therapeutic window of opportunity.

show abstract

Section: Description Of Initial-onset and Chronic Vkh Diseasementioning

confidence: 99%

Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review

Urzua

Herbort²,

Takeuchi

et al. 2022

J Ophthal Inflamm Infect

Self Cite

View full text Add to dashboard Cite

show abstract

“…VKH disease is a bilateral uveitis, and even if ocular inflammation is clinically observed in only the unilateral eye, binocular abnormalities are usually depicted by ICGA. [ 30 31 32 ] Therefore, the analysis of ocular findings was performed in both eyes.…”

Section: Ethodsmentioning

confidence: 99%

Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus

Takeuchi

Nakai

Usui

et al. 2022

Saudi Journal of Ophthalmology

View full text Add to dashboard Cite

PURPOSE: We investigated the efficacy and safety of adalimumab (ADA) treatment for chronic recurrent Vogt-Koyanagi-Harada (VKH) patients with sunset glow fundus (SGF). METHODS: Medical records of 50 chronic recurrent VKH patients with SGF who received ADA treatment for more than 6 months were retrospectively reviewed. RESULTS: The mean age of chronic recurrent VKH patients with SGF was 55.9 ± 14.4 years, and the male/female ratio was 26/24. Before ADA treatment, the mean daily dose of systemic corticosteroids was 16.5 ± 12.7 mg, and 22 patients (44%) were under immunosuppressors. LogMAR visual acuity (VA), flare counts, subfoveal choroidal thickness (SFCT), indocyanine green angiography scores, and corticosteroid and cyclosporine doses were significantly reduced by ADA treatment at 6 months compared to baseline. Among all parameters, flare count was significantly related to LogMAR VA. LogMAR VA was significantly related to flare counts but not to SFCT nor to ICGA scores. ADA treatment was continued in 94%. CONCLUSION: ADA was shown to be effective in achieving remission of chronic recurrent VKH disease with SGF refractory to conventional treatments, and was generally well tolerated with few serious adverse events.

show abstract

Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study

Nakai

Takeuchi

Usui

et al. 2022

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement

Cited by 4 publications

References 26 publications

Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review

Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review

Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus

Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study

Contact Info

Product

Resources

About